Cancer Stem Cell News Volume 9.30 | Aug 12 2020

    0
    429







    2020-08-12 | CSCN 9.30


    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 9.30 – 12 August, 2020
    TOP STORY

    PAF1
    Regulates Stem Cell Features of Pancreatic Cancer Cells, Independently of the PAF1 Complex, via Interactions with PHF5A and DDX3

    Researchers investigated mechanisms by which PAF1 maintains cancer stem cells and contributes to development of pancreatic tumors.
    [Gastroenterology]

    AbstractGraphical Abstract


    Watch 'collaborating to accelerate COVID-19 research'
    PUBLICATIONSRanked by the impact factor of the journal

    Serial
    Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy

    Scientists examined the prognostic significance of circulating tumor cell dynamics during treatment in metastatic breast cancer patients receiving first-line chemotherapy.
    [JNCI-Journal of the National Cancer institute]

    Abstract

    LC3B
    Upregulation by NANOG Promotes Immune Resistance and Stem-Like Property through Hyperactivation of EGFR Signaling in Immune-Refractory Tumor Cells

    The authors report that the emergence of refractory phenotypes was highly associated with an aberrant macroautophagic/autophagic state of NANOG+ tumor cells and that the autophagic phenotype arose through transcriptional induction of MAP1LC3B/LC3B by NANOG.
    [Autophagy]

    Abstract

    Broccoli
    Extract Increases Drug-Mediated Cytotoxicity towards Cancer Stem Cells of Head and Neck Squamous Cell Carcinoma

    Researchers investigated whether sulforaphane could enhance the chemotherapeutic effects of cisplatin and 5-fluorouracil against head and neck squamous cell carcinomas–cancer stem cells, and its mechanisms of action.
    [British Journal of Cancer]

    Abstract

    EGFR/FOXO3a/BIM
    Signaling Pathway Determines Chemosensitivity of BMP4-Differentiated Glioma Stem Cells to Temozolomide

    Scientists examined whether epidermal growth factor receptor (EGFR) signaling affected bone morphogenic protein 4-induced differentiation of glioma stem cells and their response to the alkylating drug temozolomide.
    [Experimental and Molecular Medicine]

    Full Article

    Antagonists
    of the Serotonin Receptor 5A Target Human Breast Tumor Initiating Cells

    Researchers found that selective antagonists of 5-HT5A reduced the frequency of tumorsphere initiating cells residing in breast tumor cell lines and those of patient-derived xenografts that they established.
    [BMC Cancer]

    Full Article

    Identification
    of a Subpopulation of Long-Term Tumor-Initiating Cells in Colon Cancer

    Based on the methods for isolating and identifying cancer stem cells and the functional features of long-term tumor-initiating cells (LT-TICs), the authors aimed to identify a subpopulation of LT-TICs.
    [Bioscience Reports]

    Abstract

    Immunogenic
    Cell Death of Breast Cancer Stem Cells by an Endoplasmic Reticulum‐Targeting Copper(II) Complex

    Investigators report a copper(II) complex containing a Schiff base ligand and a polypyridyl ligand, 4 capable of inducing immunogenic cell death in breast cancer stem cells.
    [Chembiochem]

    Abstract

    Apigenin
    Enhanced Antitumor Effect of Cisplatin in Lung Cancer via Inhibition of Cancer Stem Cells

    Scientists attempted to clarify whether apigenin could improve the antitumor efficiency of cisplatin in lung cancer using cancer stem cells.
    [Nutrition and Cancer-An International Journal]

    Abstract


    Explore virtual support and resources to stay productive and connected with your field.
    REVIEWS

    Epithelial
    Cell Adhesion Molecule: An Anchor to Isolate Clinically Relevant Circulating Tumor Cells

    The authors summarize the most significant advantages and disadvantages of using epithelial cell adhesion molecule as a marker for circulating tumor cell enrichment and its potential biological role in the metastatic cascade.
    [Cells]

    Full Article

    INDUSTRY AND POLICY NEWS

    BryoLogyx
    Announces Cooperative Research and Development Agreement for Bryostatin-1 with National Cancer Institute

    BryoLogyx, Inc. announced that it has entered into a Cooperative Research and Development Agreement with the National Cancer Institute, to conduct a Phase I clinical trial with bryostatin-1 in pediatric and young adult patients with relapsing or refractory CD22 expressing acute lymphoblastic leukemia and lymphoma.
    [BryoLogyx, Inc.]

    Press Release

    FEATURED EVENT

    Till & McCulloch Meetings 2020

    October 26 – October 28
    Virtual


    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Associate – RNA Epigenetics in Cancer Stem Cells

    Sanford Burnham Prebys Medical Discovery Institute – La Jolla, California, United States

    Faculty Position – Prostate Cancer Biology and Cancer Epigenetics

    Northwestern University – Chicago, Illinois, United States

    Postdoctoral Fellowship – Hematopoiesis, Leukemia, and Bone Marrow Failure Syndromes

    The University of Texas Southwestern Medical Center – Dallas, Texas, United States


    Postdoctoral Research Fellow – Hematopoiesis, Marrow Failure and Myeloid Leukemia

    Cincinnati Children’s Hospital Medical Center – Cincinnati, Ohio, United States

    Postdoctoral
    Positions – Cancer Epigenomics

    West Virginia University – Morgantown, West Virginia, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Science News Cancer Stem Cell News
    Archives Contact Us
    Cancer Stem Cell News Twitter